Targeting eosinophils: severe asthma and beyond
作者: Marco Caminati MD, Francesco Menzella MD, Lucia Guidolin MD, Gianenrico Senna MD
刊名: Drugs in Context, 2019
来源数据库: BioExcel Publishing Ltd
DOI: 10.7573/dic.212587
关键词: ABPABenralizumabEGPAEosinophilic esophagitisEosinophilic inflammationMepolizumabReslizumabSevere asthma
原始语种摘要: Recent research in the field of bronchial asthma has mainly focused on eosinophilic disease phenotype. Several trials proved the efficacy and safety profile of eosinophils and interleukin (IL)-5 targeting molecules, currently approved for severe asthma and available on the market. They include mepolizumab and reslizumab, IL-5 blocking molecules, and benralizumab, targeting the IL-5 receptor and eliciting a NK cell-mediated antibody-dependent cellular cytotoxicity against eosinophils. Eosinophilic inflammation represents the common pathophysiological background of several conditions, providing the rationale for the use of the same biologics beyond asthma. Although with different evidence grade, from clinical trials to case reports, anti-IL-5 biologics have been investigated in eosinophilic...
全文获取路径: PDF下载  BioExcel出版社  (合作)
分享到:

×
关键词翻译
关键词翻译
  • asthma 哮喘
  • eosinophilic 嗜曙红的
  • bronchial 支气管的
  • esophagitis 食管炎
  • inflammation 炎症
  • severe 严滥
  • targeting 导向目标
  • pneumonia 肺炎
  • allergic 变应性的
  • interleukin 白细胞间介素